Manal S Fawzy1,2, Eman A Toraih3, Elham O Hamed4, Mohammad H Hussein5, Hussein M Ismail6,7. 1. a Department of Medical Biochemistry, Faculty of Medicine , Suez Canal University , Ismailia , Egypt. 2. b Department of Biochemistry , Faculty of Medicine, Northern Border University , Saudi Arabia. 3. c Department of Histology and Cell Biology (Genetics Unit), Faculty of Medicine , Suez Canal University , Ismailia , Egypt. 4. d Department of Clinical Pathology, Faculty of Medicine , Sohag University , Sohag , Egypt. 5. e Pulmongist, Ministry of Health , Cairo , Egypt. 6. f Department of Cardiology, Faculty of Medicine , Suez Canal University , Ismailia , Egypt. 7. g Department of Medicine, College of Medicine , Taibah University , Almadinah Almunawwarah , Kingdom of Saudi Arabia.
Abstract
BACKGROUND: Circulating microRNAs could be powerful markers of acute myocardial infarction (MI) and its functional genetic variants could increase susceptibility to cardiovascular disease (CVD). The current study aimed to quantify the microRNA (miR)-499a levels in serum of MI patients compared to hypertensive and healthy subjects and to investigate the association of its A/G variant rs3746444 with CVD in a sample of an Egyptian population. METHODS: Serum miR-499a relative expressions were measured in 110 acute MI patients, 76 hypertensive patients, and 121 healthy controls by Real-time quantitative polymerase chain reaction. MIR-499a genotyping was performed for an additional 107 coronary artery disease patients by Real-time allele discrimination assay. RESULTS: Acute MI patients showed high relative expression of miR-499a (> 105-fold, p < .001), and it was nearly undetectable in healthy controls and hypertensive patients. It showed an area under the curve of 0.953, with a sensitivity of 97.2% and a specificity of 75.0%. ST-elevation MI (STEMI) patients had higher miR-499a serum levels than patients with Non-STEMI. There was a significant association of MIR-499a variant with acute MI but not with hypertension under all genetic models tested. As a new finding, in overall and stratified analysis, the miR-499a variant was not correlated with its expression profile. CONCLUSIONS: Circulating miR-499a levels could be a useful biomarker, discriminating acute MI within 12 hours from healthy subjects. Its variant rs3746444 A/G is associated with increased susceptibility to acute MI and CAD in Egyptian population.
BACKGROUND: Circulating microRNAs could be powerful markers of acute myocardial infarction (MI) and its functional genetic variants could increase susceptibility to cardiovascular disease (CVD). The current study aimed to quantify the microRNA (miR)-499a levels in serum of MI patients compared to hypertensive and healthy subjects and to investigate the association of its A/G variant rs3746444 with CVD in a sample of an Egyptian population. METHODS: Serum miR-499a relative expressions were measured in 110 acute MI patients, 76 hypertensivepatients, and 121 healthy controls by Real-time quantitative polymerase chain reaction. MIR-499a genotyping was performed for an additional 107 coronary artery diseasepatients by Real-time allele discrimination assay. RESULTS: Acute MI patients showed high relative expression of miR-499a (> 105-fold, p < .001), and it was nearly undetectable in healthy controls and hypertensivepatients. It showed an area under the curve of 0.953, with a sensitivity of 97.2% and a specificity of 75.0%. ST-elevation MI (STEMI) patients had higher miR-499a serum levels than patients with Non-STEMI. There was a significant association of MIR-499a variant with acute MI but not with hypertension under all genetic models tested. As a new finding, in overall and stratified analysis, the miR-499a variant was not correlated with its expression profile. CONCLUSIONS: Circulating miR-499a levels could be a useful biomarker, discriminating acute MI within 12 hours from healthy subjects. Its variant rs3746444 A/G is associated with increased susceptibility to acute MI and CAD in Egyptian population.
Authors: Eman A Toraih; Aya El-Wazir; Saleh A Alghamdi; Ayman S Alhazmi; Mohammad El-Wazir; Mohamed M Abdel-Daim; Manal S Fawzy Journal: Genet Mol Biol Date: 2019-11-14 Impact factor: 1.771
Authors: Imadeldin Elfaki; Rashid Mir; Mohammad Muzaffar Mir; Faisel M AbuDuhier; Abdullatif Taha Babakr; Jameel Barnawi Journal: J Pers Med Date: 2019-11-25
Authors: Tirza Gabrielle Ramos de Mesquita; José do Espírito Santo Junior; Thais Carneiro de Lacerda; Krys Layane Guimarães Duarte Queiroz; Cláudio Marcello da Silveira Júnior; José Pereira de Moura Neto; Lissianne Augusta Matos Gomes; Mara Lúcia Gomes de Souza; Marcus Vinitius de Farias Guerra; Rajendranath Ramasawmy Journal: PLoS Negl Trop Dis Date: 2021-09-20
Authors: Manal S Fawzy; Essam Al Ageeli; Saeed Awad Al-Qahtani; Baraah T Abu Alsel; Shahad W Kattan; Walla Alelwani; Eman A Toraih Journal: Exp Ther Med Date: 2021-11-22 Impact factor: 2.447
Authors: Eman A Toraih; Mohammad H Hussein; Essam Al Ageeli; Eman Riad; Nouran B AbdAllah; Ghada M Helal; Manal S Fawzy Journal: Respir Res Date: 2017-09-08
Authors: Joseane Biso de Carvalho; Guilherme Loss de Morais; Thays Cristine Dos Santos Vieira; Natana Chaves Rabelo; Juan Clinton Llerena; Sayonara Maria de Carvalho Gonzalez; Ana Tereza Ribeiro de Vasconcelos Journal: Front Genet Date: 2019-11-13 Impact factor: 4.599